THE UNIVERSITY OF ZAMBIA

SCHOOL OF MEDICINE

OCCURRENCE OF ADVERSE HEMATOLOGICAL EVENTS AT ONE AND SIX WEEKS IN INFANTS FOLLOWING PERINATAL EXPOSURE TO ANTIRETROVIRAL DRUGS FOR THE PREVENTION OF MOTHER TO CHILD TRANSMISSION OF HIV AT UTH.

BY

DR MUSAKU MWENECHANYA

A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENT FOR THE AWARD OF MASTERS OF MEDICINE IN PAEDIATRICS AND CHILD HEALTH

© 2010
COPYRIGHT

Dr Musaku Mwenechanya

2010

All rights reserved; no part of this dissertation may be reproduced, stored in a retrieval system or transmitted in any form by any other means, electronic, mechanical, photocopying or recording without prior consent from the author.
DECLARATION

I hereby declare that this dissertation represents my own work and has not been presented either wholly or in part for a degree at the University of Zambia or any other University.

Signed:  __________________________________________________

Student: Dr Musaku Mwenechanya BSc Hb, MBChB,

Signed:  __________________________________________________

Supervisor:  Dr Veronica Mulenga, MBChB, MMed (Paediatrics)
APPROVAL

This dissertation of Dr Musaku Mwenechanya has been approved as fulfilling the requirement of the award of the Degree of Master of Medicine in Paediatrics and Child Health by the University of Zambia

Signed: ________________________________________________________________

Head of Department

Paediatrics and Child Health

University Teaching Hospital

Examiners

Name: ________________________________________________________________

Signature: ____________________________________________________________

Date: ___________________________________________________________________

Name: ________________________________________________________________

Signature: ____________________________________________________________

Date: ___________________________________________________________________
DEDICATIONS

To my lovely wife Mpande whose patience and understanding while I took time to do this, provided me with strength to put this together.

To my son Chuya, the light and driving force behind everything I do. All this is for you.

To my parents, whose support for my education has been unchanged from the very beginning.
ACKNOWLEDGEMENTS

I wish to thank my Supervisors Dr V Mulenga and Dr C Kankasa for their constant constructive criticism that enabled me to understand research more and more

To Dr N Chintu with whom the idea of this research was built. I would like to thank her for taking time off her busy schedule to put my ideas into a sensible research proposal.

To my research assistant Hope Phiri, without your dedication to this work it would have been impossible to get this done. Special thanks to Elizabeth Sitali from Adult infectious Diseases Centre (AIDC), University Teaching Hospital, for availing us a room to carry out this project.

Extra special thanks to Vanderbilt University for providing the financial support so desperately needed to enable this research take off

To the mothers who willingly brought their babies to participate in the study. You made it a success!
**ABBREVIATIONS AND ACRONYMS**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>3TC</td>
<td>Lamuvidine</td>
</tr>
<tr>
<td>ART</td>
<td>Antiretroviral Therapy</td>
</tr>
<tr>
<td>AIDC</td>
<td>Adult Infectious Diseases Centre</td>
</tr>
<tr>
<td>AZT</td>
<td>Azidothymidine</td>
</tr>
<tr>
<td>HAART</td>
<td>Highly Active Anti-retroviral Therapy</td>
</tr>
<tr>
<td>HIV</td>
<td>Human Immunodeficiency virus</td>
</tr>
<tr>
<td>MOH</td>
<td>Ministry of Health</td>
</tr>
<tr>
<td>MTCT</td>
<td>Mother to Child Transmission</td>
</tr>
<tr>
<td>NRTI</td>
<td>Nucleoside Reverse Transcriptase Inhibitor</td>
</tr>
<tr>
<td>NNRTI</td>
<td>Non- Nucleoside Reverse Transcriptase Inhibitor</td>
</tr>
<tr>
<td>NVP</td>
<td>Niverapine</td>
</tr>
<tr>
<td>PMTCT</td>
<td>Prevention of Mother to Child transmission</td>
</tr>
<tr>
<td>PACTG</td>
<td>Paediatric Aids Clinical Trial Group</td>
</tr>
<tr>
<td>PI</td>
<td>Protease Inhibitor</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organisation</td>
</tr>
<tr>
<td>RPR</td>
<td>Rapid Plasma Reagent</td>
</tr>
</tbody>
</table>

**Definitions**

**HAART** - In this study defined as ‘use of two NRTI + one NNRTI

**Adverse Hematological events** - determined by comparing values obtained to defined normal
Abstract

Perinatal transmission of Human Immunodeficiency Virus (HIV) from mother to her new born can be prevented in most cases using a combination of Antiretroviral drugs reducing the risk to less than one percent (1%). However despite the beneficial effects of these drugs, maternal-fetal transfer of these potentially toxic drugs during pregnancy is of increasing concern. Among other concerns, of note is adverse hematological events both in the short and long term and this remains largely unknown with contradictory findings in the few studies done.

The aim of this study was to document the short term hematological outcomes at one week and six weeks in infants perinatally exposed to Antiretroviral Drugs used for the prevention of Mother to Child Transmission of HIV at UTH.

One hundred and thirty-nine HIV exposed but uninfected infants as confirmed by DNA/PCR at six weeks, were prospectively followed up until six weeks of age. Perinatal transmission prophylaxis regimens comprised Zidovudine (AZT) based regimens and non-AZT based regimens. Blood counts and differentials were determined at one and six weeks and adverse hematological events were documented and compared with documented normal values. The main focus was to document hemoglobin, absolute neutrophil and platelet count indices at one and six weeks. Data was further analysed according whether maternal prophylaxis included AZT or another nucleoside reverse transcriptase inhibitor.

The proportion of infants that were found to have anaemia was 13.5% at one week and this increased to 20.3% at 6 weeks. This study found 13.5% and 21.3% of infants developed neutropenia at one and six weeks respectively and 0.06 and 0.1% of infants developed thrombocytopenia at one and six weeks respectively in preterm babies. In term babies the proportion of neutropenia increased from 13.5% at one week to 24.1% at six weeks while the proportion of thrombocytopenia reduced from 4.1% at one week to 3.5% at six weeks.
This study shows that a significant proportion of infants developed anaemia and neutropenia following prenatal and postnatal exposure to antiretroviral drugs. However, the proportion was less so with thrombocytopenia.